Alkeus Pharmaceuticals
Biotechnology, 1 Marina Park Dr, Cambridge, Massachusetts, 02210, United States, 1-10 Employees
Phone Number: 80********
Who is ALKEUS PHARMACEUTICALS
Join our growing team! Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead...
Read More
-
Headquarters: 1 Marina Park Dr, Cambridge, Massachusetts, 02210, United States
-
Date Founded: 2010
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
Does something look wrong? Fix it. | View contact records from ALKEUS PHARMACEUTICALS
Alkeus Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Alkeus Pharmaceuticals
Answer: Alkeus Pharmaceuticals's headquarters are located at 1 Marina Park Dr, Cambridge, Massachusetts, 02210, United States
Answer: Alkeus Pharmaceuticals's phone number is 80********
Answer: Alkeus Pharmaceuticals's official website is https://alkeus.com
Answer: Alkeus Pharmaceuticals's revenue is Under $1 Million
Answer: Alkeus Pharmaceuticals has 1-10 employees
Answer: Alkeus Pharmaceuticals is in Biotechnology
Answer: Alkeus Pharmaceuticals contact info: Phone number: 80******** Website: https://alkeus.com
Answer: Join our growing team! Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month